MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-020-0838-5

Медицинская библиотека · Leukemia · 2020

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Wulf Gerald G, Altmann Bettina, Ziepert Marita, D'Amore Francesco, Held Gerhard, Greil Richard, Tournilhac Olivier, Relander Thomas, Viardot Andreas, Wilhelm Martin, Wilhelm Christian, Pezzutto Antonio, Zijlstra Josee M, Neste Eric Van Den, Lugtenburg Pieternella J, Doorduijn Jeanette K, Gelder Michel van, van Imhoff Gustaaf W, Zettl Florian, Braulke Friederike, Nickelsen Maike, Glass Bertram, Rosenwald Andreas, Gaulard Philippe, Loeffler Markus, Pfreundschuh Michael, Schmitz Norbert, Trümper Lorenz, ACT-2 study investigators

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61-80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%-39%], 28% [15%-40%], and 37% ([23%-50%] for A-CHOP, and 24% [12%-35%], 29% [17%-41%], and 56% [44%-69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5-1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5-1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9-2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Для цитирования: Wulf Gerald G, Altmann Bettina, Ziepert Marita, D'Amore Francesco, Held Gerhard, Greil Richard, Tournilhac Olivier, Relander Thomas, Viardot Andreas, Wilhelm Martin, Wilhelm Christian, Pezzutto Antonio, Zijlstra Josee M, Neste Eric Van Den, Lugtenburg Pieternella J, Doorduijn Jeanette K, Gelder Michel van, van Imhoff Gustaaf W, Zettl Florian, Braulke Friederike, Nickelsen Maike, Glass Bertram, Rosenwald Andreas, Gaulard Philippe, Loeffler Markus, Pfreundschuh Michael, Schmitz Norbert, Trümper Lorenz, ACT-2 study investigators. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.. Leukemia. 2020. DOI: 10.1038/s41375-020-0838-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.